Precision Medicine in Oncology®

The FDA has granted fast track designation to EO-3021 for use in select patients with claudin 18.2–expressing gastric or GEJ cancer.

BDTX-1535 yielded durable clinical activity in patients with relapsed/refractory, EGFR-mutant NSCLC harboring resistance mutations.

Krishnansu S. Tewari, MD, and Kimberly Futch, MBA, detail considerations with AI programs, and roles AI may have in early diagnosis, time reduction in the examination of scans, and more.

Adjuvant ribociclib receives FDA approval for HR+ breast cancer, AMG 193 elicits responses in MTAP-deleted solid tumors, and more this week from OncLive.

Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.

AI models like GigaPath may pave the way for other predictive models in cancer, as it deciphers diagnoses and mutations in a more granular method.

AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses and an acceptable safety profile across patients with MTAP-deleted solid tumors.

Several novel combinations yielded high pCR and mPR rates in patients with resectable non–small cell lung cancer, according to data from the 2024 IASLC conference.

Ivonescimab produced a significant improvement in PFS vs pembrolizumab as frontline therapy in patients with PD-L1–positive advanced NSCLC.

Global surveys from 2018 and 2024 demonstrated barriers to optimizing biomarker testing for patients with early- or late-stage lung cancer.

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

The FDA approved companion diagnostics for olaparib plus abiraterone in metastatic castration-resistant prostate cancer.

Encorafenib plus binimetinib has won approval from the European Commission for use in patients with BRAF V600E-mutated, advanced non–small lung cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

Amivantamab plus chemotherapy has received European approval for EGFR-mutant non–small cell lung cancer that progressed on an EGFR TKI.

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.

Erdafitinib was approved by the European Commission for pretreated unresectable or metastatic urothelial carcinoma harboring FGFR3 alterations.

Naval G. Daver, MD, discusses efficacy and safety data from the first-in-human phase 1/2 study investigating DSP-5336 for relapsed or refractory acute leukemia.

Shipra Gandhi, MD, highlights findings with oral SERDs in HR-positive breast cancer and options to consider after progression on CDK4/6 inhibitors.

China’s National Medical Products Administration has approved fulzerasib for the treatment of adult patients with advanced KRAS G12C–mutant NSCLC.

In 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses.

Aadi Bioscience will end the PRECISION 1 trial evaluating nab-sirolimus in solid tumors harboring TSC1/2 alterations.

Luis E. Raez, MD, FACP, FCCP, FASCO, discusses the FDA approval of repotrectinib for NTRK-positive advanced solid tumors.

The FDA has approved first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

Noah Kalman, MD, MBA, details new technology for treating head and neck cancer, and ongoing trials examining therapies at Miami Cancer Institute.

Suzanne Lentzsch, MD, PhD, discusses updated data from the LINKER-MM1 study of linvoseltamab in relapsed/refractory multiple myeloma.

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

AC699 has won fast track designation from the FDA for select patients with ER-positive, HER2-negative, ESR1-mutated breast cancer.

The acceleration of targeted therapy drug development has led investigators to home in on RAS mutations as agents are approved in colorectal cancer.